BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20178853)

  • 21. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
    Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Evaluation of clinical outcomes of allogeneic hematopoietic stem cell transplantation for relapsed/refractory peripheral T-cell lymphoma with chemoresistance].
    Wang L; Li NN; Wang Z; Wu XX; Dong YJ; Fu XR; Liu Y; Hu LD; Li XF; Wang YN; Wu YM; Ren HY; Zhang MZ; Wang MH; Li YH; Liu DH; Huang WR
    Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(48):3786-3791. PubMed ID: 31874515
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study.
    Çiftçiler R; Göker H; Demiroğlu H; Aladağ E; Aksu S; Haznedaroğlu İC; Sayınalp N; Özcebe O; Tekin F; Büyükaşık Y
    Turk J Haematol; 2019 May; 36(2):88-96. PubMed ID: 30717586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
    Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
    Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
    Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
    Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
    Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation.
    Mohty M; Boiron JM; Damaj G; Michallet AS; Bay JO; Faucher C; Perreau V; Bilger K; Coso D; Stoppa AM; Tabrizi R; Gastaut JA; Michallet M; Maraninchi D; Blaise D
    Bone Marrow Transplant; 2004 Jul; 34(1):77-84. PubMed ID: 15133485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning.
    Lee CK; Badros A; Barlogie B; Morris C; Zangari M; Fassas A; van Rhee F; Cottler-Fox M; Jacobson J; Thertulien R; Muwalla F; Mazher S; Anaissie E; Tricot G
    Exp Hematol; 2003 Jan; 31(1):73-80. PubMed ID: 12543109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioimmunotherapy in Combination with Reduced-Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation in Patients with Advanced Multiple Myeloma.
    Fasslrinner F; Stölzel F; Kramer M; Teipel R; Brogsitter C; Morgner A; Arndt C; Bachmann M; Hänel M; Röllig C; Kotzerke J; Schetelig J; Bornhäuser M
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):691-697. PubMed ID: 31730919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigens receptor T cell therapy as a bridge to haematopoietic stem cell transplantation for refractory/ relapsed B-cell acute lymphomalastic leukemia.
    Zhang Y; Chen H; Song Y; Tan X; Zhao Y; Liu X; Li Z; Yang F; Jiang M; Gao Z; Wu T
    Br J Haematol; 2020 Apr; 189(1):146-152. PubMed ID: 31869864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolving strategies with immunomodulating drugs and tandem autologous/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients.
    Michallet M; Sobh M; El-Cheikh J; Morisset S; Sirvent A; Reman O; Cornillon J; Tabrizi R; Milpied N; Harousseau JL; Labussière H; Nicolini FE; Attal M; Moreau P; Mohty M; Blaise D; Avet-Loiseau H
    Exp Hematol; 2013 Dec; 41(12):1008-15. PubMed ID: 23994781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival.
    Dhakal B; D'Souza A; Martens M; Kapke J; Harrington AM; Pasquini M; Saber W; Drobyski WR; Zhang MJ; Hamadani M; Hari PN
    Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):379-86. PubMed ID: 27160644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience.
    Piñana JL; Valcárcel D; Martino R; Barba P; Moreno E; Sureda A; Vega M; Delgado J; Briones J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):21-9. PubMed ID: 19135939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.
    Koehne G; Giralt S
    Curr Opin Oncol; 2012 Nov; 24(6):720-6. PubMed ID: 22960558
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.
    Brown JR; Kim HT; Armand P; Cutler C; Fisher DC; Ho V; Koreth J; Ritz J; Wu C; Antin JH; Soiffer RJ; Gribben JG; Alyea EP
    Leukemia; 2013 Feb; 27(2):362-9. PubMed ID: 22955330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
    de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
    Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia (CLL) patients with the aberration of p53 gene].
    Wang L; Miao K; Fan L; Xu J; Wu H; Li J; Xu W
    Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):308-12. PubMed ID: 27093994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation.
    Kim SY; Lee H; Han MS; Shim H; Eom HS; Park B; Kong SY
    Clin Lymphoma Myeloma Leuk; 2016 Sep; 16(9):527-535.e2. PubMed ID: 27375156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Allogeneic hematopoetic stem-cell transplantation for patients with relapsed or refractory lymphomas: comparison of high-dose conventional conditioning versus fludarabine-based reduced-intensity regimens.
    Bertz H; Illerhaus G; Veelken H; Finke J
    Ann Oncol; 2002 Jan; 13(1):135-9. PubMed ID: 11863095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.